Nearly two-thirds of patients hospitalized with flu, RSV, or COVID-19 received antibiotics, but they had a higher risk of death than those who didn't.
The advisory group's strong approval comes a day after it recommended Pfizer's RSV vaccine on a closer vote for the same age-group.
The group raised concerns about a small number of Guillain-Barre syndrome cases in vaccine recipients and wanted more data, especially on efficacy in those at highest risk.
The Department of Energy, with "low confidence," says SARS-CoV-2 may have come from a lab, and a controversial doctors groups touts ivermectin for the flu and RSV.
The FDA has granted RSVpreF priority review for use in pregnant women to help protect babies against the virus.
In another COVID development, the FDA pulled its EUA for Evusheld, the last available monoclonal antibody treatment, due to weak activity against the newer circulating subvariants.
Amid rising flu activity causing decade-high hospitalization rates, COVID-19 markers are also climbing.
The early flu surge is adding to pressure on health systems as they face other respiratory diseases like RSV.
In some nations in the Americas, 3 viral diseases are straining hospitals.
Flu activity in the Northern Hemisphere is rising, with levels up sharply over the past few weeks in North America, the World Health Organization (WHO) said yesterday in its latest global flu update, which roughly covers the last half of October.
